News

Europe’s firms ramp up R&D
Enlarge image

BusinessEU

Europe’s firms ramp up R&D

07.12.2012 - According to the 2011 EU Industrial R&D Investment Scoreboard, the 400 leading European companies invested about €132bn, a plus of 6.1% over 2009.

R&D investment by top EU companies recovered strongly in 2010. The annually published Scoreboard collects information on the top 1000 EU companies and 1000 non-EU companies investing the largest sums in research and development. What seems to be a positive trend as a first glance, shows some worrying trends at closer inspection. The study, which was commissioned by the European Commission, has shown that EU companies as a whole are lagging behind major competitors from the US and some Asian economies on R&D growth. While EU-based companies increased R&D expenditures by 6.1%, US-companies have spent 10% more. The increase was even larger in Taiwan (17.8%), South Korea (20.5%) and China(29.5%).

The global top 50, in terms of total R&D investment, includes 15 EU companies, 18 US firms and 13 from Japan. Two pharmaceutical companies occupied the top spots: Roche from Switzerland (€7.2bn) followed by Pfizer from the US (€7bn). A ray of light: A poll with some 190 mainly larger EU-companies surveyed in the Scoreboard revealed that they expect to maintain robust R&D investment increases (average 4% p.a.) over the next three years. This could be seen as a positive and stable trend for R&D investment growth, as observed before the 2008 economic and financial crises.

The Pharmaceuticals & Biotechnology sector has strengthened its position as the largest sector for R&D, its expenditures grew by 6.2% in 2010, slightly more than in 2009. The other two top sectors, Technology Hardware & Equipment and Automobiles & Parts are recovering from the significant reductions observed in the past Scoreboard (from -6.4% to 3.5% and from -11.6% to 0% respectively). Interestingly, all three sectors increased net sales more than they increased R&D investments.

Máire Geoghegan-Quinn, Commissioner for Research, Innovation and Science sees room for further improvement. „We need quick adoption and implementation of recent and up-coming European Commission proposals on the unitary patent, on standards, public procurement and risk capital“, she said. 

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-04/europes-firms-ramp-up-rd.html

BusinessGermany

31.03.2015 Merck Serono has forged a US$941m (€876m) deal with US Intrexon for the development and commercialisation of CAR-T therapies. The new CAR-T projects are set to strengthen their R&D technology portfolio in immuno-oncology.

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

FinancingGermany

10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC1.28 EUR10.34%
  • BASILEA110.70 CHF2.31%
  • BIOTEST98.10 EUR2.29%

FLOP

  • PAION2.36 EUR-6.72%
  • MOLOGEN5.45 EUR-4.22%
  • WILEX3.01 EUR-2.90%

TOP

  • CYTOS1.43 CHF320.6%
  • MEDIGENE12.31 EUR189.6%
  • 4SC1.28 EUR64.1%

FLOP

  • MORPHOSYS58.81 EUR-21.3%
  • WILEX3.01 EUR-12.2%
  • BASILEA110.70 CHF-9.4%

TOP

  • SANTHERA93.75 CHF2214.8%
  • FORMYCON26.94 EUR271.6%
  • WILEX3.01 EUR220.2%

FLOP

  • CYTOS1.43 CHF-52.3%
  • MOLOGEN5.45 EUR-52.0%
  • PAION2.36 EUR-35.0%

No liability assumed, Date: 31.03.2015